CD274 and cancer: Interestingly, the contribution of IRF1 to CD274 expression relative to that of other significant TFs differed amongst cancer types (15% [SD: 1.4] in BRCA, 26% [SD: 2.1] in LUAD, and 56% [SD: 3.9] in SKCM).